These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 5787285)
41. [Treatment of some vascular diseases with the use of oxyphenyl-oxybutylamino-ethanol]. Berezovsky M; Berstein S Prensa Med Argent; 1966 Sep; 53(36):1964-71. PubMed ID: 4384691 [No Abstract] [Full Text] [Related]
43. The treatment of peripheral vascular disease. Forrest H Practitioner; 1975 Oct; 215(1288):431-7. PubMed ID: 1105540 [No Abstract] [Full Text] [Related]
44. [Influence of several drugs of the adrenergic sphere on rat paw inflammatory edema. I. Action of naphtazoline, ephedrine, metaraminol, bamethan, yohimbin and propranolol]. Marçais H; Marcy R C R Seances Soc Biol Fil; 1970; 164(4):773-5. PubMed ID: 4396653 [No Abstract] [Full Text] [Related]
45. Evaluation of a new alpha-blocking vasodilator agent (thymoxamine) in peripheral vascular disease. Kane SP Br J Surg; 1970 Dec; 57(12):921-6. PubMed ID: 4395088 [No Abstract] [Full Text] [Related]
46. Untoward hemodynamic effects of intra-arterial injections of vasodilator drugs on the muscle circulation in the dog hind limb with experimental arterial occlusion. Lambert J; Lambert PJ Angiology; 1967 Jul; 18(7):415-27. PubMed ID: 6028457 [No Abstract] [Full Text] [Related]
47. [Experiences with a new phytotherapeutic vasomotor drug]. Leimbach H Landarzt; 1966 Sep; 42(26):1156-9. PubMed ID: 5916904 [No Abstract] [Full Text] [Related]
48. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin]. Belcaro G; Cesarone MR Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443 [TBL] [Abstract][Full Text] [Related]
49. [Treatment of angiodystrophic skin diseases with ginkgo-biloba]. Nazzaro P; Di Carlo A Minerva Med; 1973 Nov; 64(79 Suppl):4198-200. PubMed ID: 4592297 [No Abstract] [Full Text] [Related]
50. [The therapeutic effects of flunarizine in peripheral arterial diseases and cerebrovascular diseases]. De Gregorio G; Restivo S Clin Ter; 1982 Dec; 103(5):501-7. PubMed ID: 7160142 [No Abstract] [Full Text] [Related]
54. [Experience with the vasodilator agent spasmocyclone]. Priessnitz O Med Welt; 1966 Jun; 26():1433-6. PubMed ID: 5962718 [No Abstract] [Full Text] [Related]
55. A randomized trial of iloprost in patients with intermittent claudication. Creager MA; Pande RL; Hiatt WR Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433 [TBL] [Abstract][Full Text] [Related]
56. [Clinical use of thymoxamine in peripheral arterial pathology]. Ghiglino GC; Viacava A; Gori A; Misuri A; Lucertini G; Pelagatti M Clin Ter; 1983 Apr; 105(2):103-7. PubMed ID: 6222862 [No Abstract] [Full Text] [Related]
57. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Mohler ER; Klugherz B; Goldman R; Kimmel SE; Wade M; Sehgal CM Vasc Med; 2000; 5(4):231-7. PubMed ID: 11213235 [TBL] [Abstract][Full Text] [Related]
58. Drugs for ischemic peripheral arterial disease. Med Lett Drugs Ther; 1978 Jan; 20(2):11. PubMed ID: 339049 [No Abstract] [Full Text] [Related]
59. [The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication]. Komarov AL; Panchenko EP; Eshkeeva AR; Dobrovol'skiĭ AB; Titaeva EV; Karpov IuA Ter Arkh; 1996; 68(2):49-53. PubMed ID: 8771659 [TBL] [Abstract][Full Text] [Related]
60. [Pharmacology of peripheral sympathomimetics & the conclusions drawn from it for the treatment of shock & collapse]. SCHNEIDER KW Dtsch Med J; 1958 May; 9(5):236-9. PubMed ID: 13547916 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]